Analysis demonstrates survival differences based on glycolysis and cholesterol synthesis-related genes in lung adenocarcinoma, suggesting potential therapeutic targets.
We have made the necessary revisions to the summary as requested. The revised summary is as follows: This study aimed to construct a prognostic model for LUAD based on glycolysis- and cholesterol synthesis-related genes (GCSRGs). By performing regression analyses on expression profiles and clinical data from public databases, we established a robust risk stratification system. The results revealed significant survival differences between high- and low-risk groups, with the low-risk group exhibiting stronger immune cell infiltration and higher immune scores. Drug sensitivity analysis suggested that amonafide, AM-5992, and AZD-3147 may serve as potential therapeutic candidates. In conclusion, this model enables precise survival prediction and provides valuable insights for personalized immunotherapy and targeted treatment.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: